Press Release
Arena Pharmaceuticals to Present New Preclinical Atopic Dermatitis Data for Etrasimod at the European Society for Dermatologic Research Annual Meeting
Presentation Details:
Title: Etrasimod, an Oral, Selective Sphingosine 1-Phosphate Receptor Modulator Improves Skin Inflammation in a Contact Hypersensitivity Model of Dermatitis
Poster Number: 30
The e-poster abstract was also selected for presentation as part of the Inflammation, Immunity and Infection poster walk.
Poster Walk Details:
Walk Title: Inflammation, Immunity and Infection 7: Innate immunity and skin Inflammation
Walk Session: Walk 21 (Kiosk 1)
Walk Time:
About
Arena has additional license agreements and partnerships, including with
Forward-Looking Statements
Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. These forward-looking statements may be identified by introductory words such as "will," "in development for," "expected," "later this year," "driven to," "potentially," "potential," "evaluating," or words of similar meaning, or by the fact that they do not relate strictly to historical or current facts. Such forward-looking statements include statements about Arena's participation in the upcoming meeting; the opportunity, development and potential of etrasimod, including the expected initiation of a trial in atopic dermatitis; Arena's drive; and the potential of Arena's assets, programs, licenses, and partnerships. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include those disclosed in Arena's filings with the
Corporate Contact:
Executive Vice President and
Chief Financial Officer
klind@arenapharm.com
858.210.3636
Media Contact:
Matt Middleman, MD
LifeSci Public Relations
matt.middleman@lifescipublicrelations.com
646.627.8384
View original content to download multimedia:http://www.prnewswire.com/news-releases/arena-pharmaceuticals-to-present-new-preclinical-atopic-dermatitis-data-for-etrasimod-at-the-european-society-for-dermatologic-research-annual-meeting-300919341.html
SOURCE